In contrast, ibrutinib-treated mice with HUS showed elevated, but not significantly altered, plasma NGAL compared with their corresponding sham group as well as significantly less plasma NGAL compared with vehicle-treated mice with HUS. The gene discussed is LCN2; the disease is hemolytic-uremic syndrome.